Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Naluzotan hydrochloride (PRX 00023 hydrochloride) is a hERG K+ channel blocker with an IC50 value of 3800 nM and is commonly used in the study of anxiety and depression.Naluzotan hydrochloride is also a novel, potent, and selective 5-HT1A agonist, with an IC50 value of about 20 nM and a Ki value of about 5.1 Naluzotan hydrochloride is also a novel, potent and selective 5-HT1A agonist with an IC50 of approximately 20 nM and a Ki of approximately 5.1 nM.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 53,000 |
5 mg | 在庫あり | ¥ 131,000 |
10 mg | 在庫あり | ¥ 187,500 |
25 mg | 在庫あり | ¥ 287,000 |
50 mg | 在庫あり | ¥ 385,500 |
100 mg | 在庫あり | ¥ 521,000 |
500 mg | 在庫あり | ¥ 1,044,500 |
説明 | Naluzotan hydrochloride (PRX 00023 hydrochloride) is a hERG K+ channel blocker with an IC50 value of 3800 nM and is commonly used in the study of anxiety and depression.Naluzotan hydrochloride is also a novel, potent, and selective 5-HT1A agonist, with an IC50 value of about 20 nM and a Ki value of about 5.1 Naluzotan hydrochloride is also a novel, potent and selective 5-HT1A agonist with an IC50 of approximately 20 nM and a Ki of approximately 5.1 nM. |
ターゲット&IC50 | 5-HT1A:20 nM, 5-HT1A:5.1 nM, ERG K+ (human):3800 nM |
In vitro | Naluzotan hydrochloride behaves as a full agonist in an in vitro cell-based functional assay with an EC50 of 20 nM. Naluzotan hydrochloride has significant affinity is the guinea pig sigma receptor (Ki = 100 nM), but does not inhibit cytochrome P450 isoforms (CYP) 1A2, 2C9, 2C19, 2D6, and 3A4.[1] |
In vivo | In rats Naluzotan hydrochloride shows 11% oral bioavailability with a serum t1/2 of 2−3.5 h when administrated po, attaining a Cmax level of 24 ± 13 ng/mL (3 mg/kg, po). Naluzotan hydrochloride shows significant brain penetration, achieving a brain:serum concentration ratio of approximately 0.5 in the rat at 1 h following either intravenous or oral administration and reaching brain concentration approximately equivalent to that of buspirone. In dogs the pharmacokinetic profile of Naluzotan hydrochloride shows 16% oral bioavailability, a serum t1/2 of 1.1 h po, and a Cmax level of 174 ± 141 ng/mL (3 mg/kg, po)[1]. PRX-00023 (0.01-0.05 mg/kg, i.p.) significantly reduces USV rates, but done of these doses produce sedation in rats.[2] |
別名 | PRX 00023 hydrochloride |
分子量 | 487.1 |
分子式 | C23H39ClN4O3S |
CAS No. | 740873-82-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (102.65 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Naluzotan hydrochloride 740873-82-9 Angiogenesis GPCR/G Protein JAK/STAT signaling Neuroscience Tyrosine Kinase/Adaptors EGFR 5-HT Receptor PRX 00023 hydrochloride Naluzotan Hydrochloride PRX 00023 Hydrochloride PRX00023 Hydrochloride PRX-00023 Hydrochloride Inhibitor inhibitor inhibit